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Abstract
Background: Both sleep duration and sleep quality are related to future health, but their combined effects on mortality are
unsettled. We aimed to examine the individual and joint effects of sleep duration and sleep disturbances on cause-specific
mortality in a large prospective cohort study.
Methods: We included 9,098 men and women free of pre-existing disease from the Whitehall II study, UK. Sleep measures
were self-reported at baseline (1985–1988). Participants were followed until 2010 in a nationwide death register for total
and cause-specific (cardiovascular disease, cancer and other) mortality.
Results: There were 804 deaths over a mean 22 year follow-up period. In men, short sleep (#6 hrs/night) and disturbed
sleep were not independently associated with CVD mortality, but there was an indication of higher risk among men who
experienced both (HR= 1.57; 95% CI: 0.96–2.58). In women, short sleep and disturbed sleep were independently associated
with CVD mortality, and women with both short and disturbed sleep experienced a much higher risk of CVD mortality (3.19;
1.52–6.72) compared to those who slept 7–8 hours with no sleep disturbances; equivalent to approximately 90 additional
deaths per 100,000 person years. Sleep was not associated with death due to cancer or other causes.
Conclusion: Both short sleep and disturbed sleep are independent risk factors for CVD mortality in women and future
studies on sleep may benefit from assessing disturbed sleep in addition to sleep duration in order to capture health-relevant
features of inadequate sleep.
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Introduction
Inadequate sleep is under-recognized as a problem in modern
society, although it has been estimated that about one in five adults
are affected by sleep problems [1]. Findings from two recent
independent systematic reviews and meta-analyses show a U-
shaped association between sleep duration and mortality with both
short and long sleep being predictors of all-cause mortality [2,3].
Associations between sleep duration and cause-specific mortality
present a more mixed picture with associations between CVD,
cancer and ‘other’ deaths observed for both short and long sleep in
some, but not all, studies [4].
While most studies have focused on the health effects of sleep
duration, poor sleep quality may also be important for health.
Disturbed sleep is likely to suppress slow wave sleep, which
facilitates general biological restoration, and a recent experimental
study found that reduced sleep quality, without changes in sleep
duration, was associated with decreased insulin sensitivity and
glucose tolerance [5]. Only a few population studies have
addressed the association between sleep disturbances and mortal-
ity. While there have been inconsistencies in the results [4], we
have recently observed a relatively strong association between
sleep disturbances and premature death in a cohort of French men
and women [6].
While even less work has examined both sleep duration and
sleep disturbances, findings from the Whitehall II study showed
that the effect of short sleep duration on coronary heart disease
(CHD) incidence was greatest among those with disturbed sleep
[7]. This observation was supported by findings from a Dutch
population-based study, which showed a higher risk of CHD
incidence in short sleepers, especially if they also reported poor
sleep quality [8]. Although these results suggest that sleep duration
and sleep quality have synergistic effects on cardiovascular health,
the findings for mortality are less clear. In a smaller study
including 3,430 middle-aged Chinese adults, a higher risk of all-
cause mortality was associated with frequent insomnia among
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those sleeping more than 9 hours per night, but not among those
with shorter sleep duration [9]. In contrast, a study from the US
including 1,741 men and women showed a markedly higher risk of
all-cause mortality among men, but not women, with short sleep
duration and insomnia; a finding that was mainly confined to men
with existing hypertension or diabetes [10]. A different distribution
of causes of deaths in the two studies may explain some of the
heterogeneity in the results. In the present study we examined for
the first time both the individual and joint effects of sleep duration
and disturbed sleep on total and cause-specific (CVD, cancer and
other) mortality in a large population-based study including more
than 9,000 men and women.
Material and Methods
Study population
The target population of the Whitehall II study was all London-
based office staff aged 35 to 55 years working in 20 civil service
departments in 1985. With a response rate of 73%, the final cohort
consisted of 10,308 participants. Baseline screening (Phase 1),
between late 1985 and early 1988, involved a clinical examination
and a self-administered questionnaire. Subsequent phases of data
collection have alternated between postal questionnaire alone (all
even-numbered phases), and postal questionnaire accompanied by
clinical examination (all odd-numbered phases). Further details
have been described elsewhere [11,12]. Data from all 10,308
participants at Phase 1 were used to exclude everyone with pre-
existing chronic disease; cardiovascular disease, diabetes, cancer,
or respiratory disorders (n = 1,077), and everyone who reported
taking sleeping pills on a daily basis (n = 17). Participants with
missing information on sleep (n= 73), other covariates (n = 33) or
of uncertain vital status at the end of follow-up (n = 10) were also
excluded, leaving 6,114 men and 2,984 women for the statistical
analyses.
Sleep duration and disturbed sleep
Sleep duration was measured at Phase 1 using a single question
‘‘How many hours of sleep do you have on an average week night?’’ Response
categories were 5 hours or less, 6, 7, 8, and 9 hours or more.
Disturbed sleep was assessed by one question from the General
Health Questionnaire-3016 ‘‘Have you recently been having restless,
disturbed nights?’’ The response categories were Not at all, No more
than usual, Rather more than usual, and Much more than usual.
For the analyses, the last two categories were combined due to
small numbers in the ‘Much more than usual’ category. In order to
assess the joint effect of sleep duration and disturbances, we
constructed a new composite variable with the following catego-
ries: 7–8 hours and no sleep disturbances; 7–8 hours and
disturbed sleep; #6 hours and no sleep disturbances; and
#6 hours and disturbed sleep. Participants with 9 or more hours
of sleep were not included in this composite variable due to their
increased mortality risk compared to those sleeping 7–8 hours.
Covariates
All covariates were measured at phase 1. Sociodemographic factors
included age, marital status (married/cohabiting: yes/no), ethnic-
ity (White/non-White), and civil service employment grade, which
was categorized as low (clerical and administrative support staff),
intermediate (professional and executive staff), or high (senior
administrative staff and managers). Health-related behaviors included
smoking (never, ex-, current smoker), high alcohol consumption
(defined as $15 units/week for women and $22 units/week for
men), and physical activity (0, 1–2, 3+ hours of moderate to
vigorous physical activity per week). Physical inactivity was defined
as 0 hours of moderate to vigorous activity per week. Cardiovascular
risk factors were measured at the screening examination and
included body mass index (BMI) as kg/m2, systolic blood pressure
(mmHg), and total cholesterol (mmol/L). Depression/anxiety includ-
ed self-reported nervous trouble or persistent depression in the
preceding 12 months. As the measure on depression/anxiety was
included after the beginning of the study these data were only
available for a subset of the cohort.
Follow-up
The participants were followed from the date of the Phase 1
examination until date of death (n = 804) or end of follow-up on
31st of January 2010. Mortality follow-up was available through
the National Health Services Central Registry. Registration of
death within 5 days is a legal requirement in the UK and
participants not registered were assumed to be alive. Death
certificates were coded using the 9th and 10th revisions of the
International Classification of Disease (ICD) and categorized as
cardiovascular disease (ICD-9 codes 390–459 and ICD-10 codes
I00-I99), cancer (ICD-9 codes 140–208 and ICD-10 codes C00-
C97), and other deaths (all remaining codes).
Ethical approval
Ethical approval for the Whitehall II study was obtained from
the University College London Medical School committee on the
ethics of human research.
Statistical analysis
Cox proportional hazards models with age as the underlying
time variable were used to analyze the data. All variables met the
proportional hazards assumption. Initially, we estimated hazard
ratios (HR) and 95% confidence intervals (CI) for all-cause
mortality and cause-specific mortality according to sleep duration,
disturbed sleep, and the joint effect of the two. To assess the
absolute effects of these variables on mortality, we also used the
additive hazards model, which is a flexible semi-parametric model
for survival outcomes [13]. In that model, the hazard is modeled as
a linear function of the explanatory variables and the effect
estimates can therefore be directly interpreted as the number of
additional cases associated with the explanatory variables. We
tested the underlying assumption of age-invariant effects and
found no indication of violation. All analyses were conducted
separately for men and women.
In statistical terms, with li(t) denoting the hazard of the event in
question (e.g. total mortality) for person i at age t the following
models were employed
Cox model : li tð Þ~l0 tð Þexp aAizbXið Þ
Aalen additive hazard model : li tð Þ~~l0 tð Þz~aAizgb tð ÞXi
Where Ai is the exposure status for person i; so in the analysis of
sleep duration it would be a 5 level categorical variable and in the
analysis of disturbed sleep it would be a 3 level categorical
variable. Xi denotes potential confounders (only included in the
multiple adjusted analysis). The log hazard ratio is captured by a
while the additive effect is captured by ~a. Finally,
lo tð Þ, ~l0 tð Þ, andgb tð Þ are unspecified age dependent functions.
Using age as the time variable in both models allowed for
thorough adjustment for confounding by age.
Sleep and Cause-Specific Mortality
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e91965
There is an ongoing discussion on how to define and measure
interaction, but most health researchers would agree that
interventions or preventive strategies should be aimed at patients
or population sub-groups where most cases could potentially be
prevented [14]. In order to identify such sub-groups, deviation
from additivity of absolute effects is the relevant measure of
interest. When applying additive hazards models, the explanatory
models are fitted on an additive scale and product terms to assess
deviation from additivity of effects can be included and used to
directly obtain the number of additional deaths due to interaction
[15].
A multiple adjusted model was fitted to adjust for confounding
by baseline covariates. Potential confounders were identified based
on existing knowledge on risk factors for impaired sleep and
premature death using the methods of directed acyclic graphs [16]
and included age, ethnicity, marital status, and employment grade.
Menopausal status was also identified as a potential confounder
among women, but as several women lacked information on
menopausal status and it was not associated with total or CVD
mortality in the current study, we decided not to include the
variable in further analyses. As depression/anxiety was only
assessed in a subset, we addressed potential confounding within
this subset. Health-related behavior (alcohol, smoking, and
physical activity), and cardiovascular risk factors (BMI, systolic
blood pressure, and total cholesterol) are potential mediators of the
relation between sleep and mortality, and adjusting for these
variables could constitute over-adjustment (i.e. accounting for a
variable on the causal pathway). We therefore only adjusted for
health-related behavior and CVD risk factors in sensitivity
analyses to see how such adjustments affected our results. In
another sensitivity analysis, we also excluded the first four years of
follow-up to prevent reverse causation by ill-health induced sleep
problems. As we do not have information on sleep apnea, analyses
in a sample restricted to those of normal weight (BMI,25 kg/m2),
where the prevalence of sleep apnea is expected to be lower, were
used to assess potential confounding by sleep apnea.
Additive hazards models were fitted using the software package
R, version 2.13.1 (through the package ‘‘timereg’’, version 1.5) and
all other analyses were conducted using STATA, version 12.
Results
Baseline characteristics
Age at baseline ranged from 35 to 55 years with a mean of 45
years. Forty-four percent of the population reported either short
sleep or disturbed sleep, with 9 percent reporting both (8% men
and 11% women). Baseline characteristics of the population are
shown in Table 1.
Sleep and all-cause mortality
During the 22 years of follow-up, 804 deaths occurred (538
deaths among the 6,114 eligible men, and 266 deaths among the
2,984 eligible women). The mean age at time of death was 63
years for men and 64 years for women. Sleep duration was
associated with all-cause mortality in the expected U-shaped
fashion in both men and women, with higher risk of premature
death associated with both short and long sleep durations (Table 2).
Men who slept 6 hours versus 7 hours had a higher mortality risk
(HR=1.23; 95% CI: 1.01–1.50), but apart from this, the risk
estimates were not statistically significant. Neither disturbed sleep
on its own or disturbed sleep combined with short sleep were
associated with all-cause mortality in men or women.
Sleep and cardiovascular disease mortality
During follow-up, 167 men and 54 women died due to CVD.
Men who reported 9 hours or more of sleep appeared to be at
higher risk of CVD mortality, but the risk estimates were based on
only two CVD deaths (Table 3). Apart from this, neither short
sleep nor disturbed sleep was associated with CVD mortality in
men. However, men who reported both short and disturbed sleep
were at higher risk of CVD mortality in the age-adjusted analysis
(HR=1.66; 1.01–2.73). This risk estimate was attenuated slightly
after adjustment for other confounders (1.57; 0.96–2.58). Although
not statistically significant, there was some indication of multipli-
cative (P = 0.13) and additive (P=0.14) interaction between short
sleep and disturbed sleep in men, with an estimated 67 additional
deaths per 100,000 person years (95% CI: 223; 157) due to this
interaction.
Compared to women sleeping 7–8 hours per night, women who
slept 6 or less hours per night showed higher risk of CVD mortality
(HR=1.81; 95% CI: 1.05; 3.10), equivalent to an additional 43
deaths per 100,000 person years (Table 4). Disturbed sleep was
also associated with markedly higher risk of CVD mortality in
women (HR=3.04; 1.42–6.51), accounting for 70 additional CVD
deaths per 100,000 person years (95% CI: 19; 121). Compared to
women who slept 7–8 hours with no sleep disturbances, women
who experienced both short and disturbed sleep had a consider-
ably higher risk of CVD mortality (HR=3.19; 1.52–6.72)
equivalent to an additional 93 deaths per 100,000 person years.
However, we found no evidence of synergy, as this effect was no
more than the joint effect of the two individual risk factors (test of
additive interaction, P=0.88).
We conducted several sensitivity analyses to assess the
robustness of our findings (Table 5). We had already excluded
everyone with pre-existing disease at baseline to prevent reverse
causality (existing ill-health giving rise to sleep problems). Further
to address this issue, we also excluded deaths occurring within the
first four years of follow-up. Although this reduced the number of
deaths, we found very similar results to the main analysis (Table 5).
Adjustment for nervous trouble and persistent depression in a
subset of the population with information on this variable
(n = 6756) slightly attenuated the higher risk of CVD mortality
associated with both short and disturbed sleep in women
(HR=2.35; 95% CI: 1.04–6.12), but not in men (HR=1.87;
1.08–3.25). Further adjustments for health behaviors and CVD
risk factors did not markedly change the risk estimates (Table 5).
Further to reduce potential confounding from sleep disorders,
we also restricted the sample to those of normal weight
(BMI,25 kg/m2). This severely reduced the sample size and
especially the number of CVD deaths (to 77 in men and 20 in
women). In this reduced sample of normal-weight people, no
higher CVD mortality risk was found among men who experi-
enced both short and disturbed sleep (HR=0.74; 95% CI: 0.26–
2.05), while women with short and disturbed sleep still appeared to
be at markedly higher risk of CVD mortality (4.01; 1.15–14.0).
Sleep and cancer mortality or death due to other causes
During follow-up, 224 men and 150 women died of cancer and
143 men and 59 women died of other causes (including deaths due
respiratory diseases and external causes). Both men (HR=1.47;
0.36–6.02) and women (1.70; 0.53–5.38) who slept 9 or more
hours appeared to be at higher risk of cancer mortality, but the
confidence intervals were very broad due to the low number of
cases (Tables 3 & 4). Apart from this there were no noteworthy
associations between any of the sleep measures and deaths due to
cancer or other causes.
Sleep and Cause-Specific Mortality
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Discussion
In a large prospective population-based study of middle-aged
men and women, we found sleep duration to be associated with
all-cause mortality in the expected U-shaped manner. Short sleep
duration or disturbed sleep were not independently associated with
CVD mortality in men, but men who reported both short and
disturbed sleep appeared to be at higher risk. Associations with
CVD mortality seemed to be different for women. Both short sleep
duration and disturbed sleep were independent predictors of CVD
mortality in women, and women who experienced both short and
disturbed sleep, compared to those who slept 7–8 hours with no
Table 2. All-cause mortality associated with sleep duration and disturbed sleep among 9,098 men and women free of pre-existing
disease (cardiovascular disease, diabetes, cancer, respiratory disorders) from the Whitehall II study.
Men
No of deaths
Age-adjusted HR
(95% CI)
Multiple-adjusted{ HR
(95% CI)
Additional deaths{ per 100,000
PY (95% CI)
Sleep length
#5 hours 25 1.33 (0.88; 1.99) 1.11 (0.73; 1.68) 48 (2134; 229)
6 hours 171 1.29 (1.06;1.56) 1.23 (1.01; 1.50) 69 (24; 143)
7 hours 250 1 (Reference) 1 (Reference) 0 (Reference)
8 hours 87 1.21 (0.94; 1.54) 1.18 (0.92; 1.50) 51 (230; 132)
.9 hours 5 1.69 (0.70; 4.09) 1.44 (0.59; 3.50) 124 (2284; 532)
Restless, disturbed nights
Not at all 200 1 (Reference) 1 (Reference) 0 (Reference)
No more than usual 246 0.94 (0.78; 1.13) 0.95 (0.79; 1.14) 217 (282; 48)
More than usual 92 0.90 (0.70; 1.15) 0.92 (0.72; 1.17) 224 (299; 50)
Joint effect
7–8 h sleep and no sleep disturbances 291 1 (Reference) 1 (Reference) 0 (Reference)
Disturbed sleep only 46 0.84 (0.61; 1.15) 0.85 (0.62; 1.16) 238 (2117; 41)
#6 h sleep only 150 1.19 (0.98; 1.45) 1.13 (0.93; 1.38) 44 (233; 122)
#6 h sleep & disturbed sleep 46 1.22 (0.90; 1.67) 1.18 (0.86; 1.61) 61 (254; 175)
Interaction
P-value for interaction 0.39 0.39 0.47
Additional deaths due to interaction 54 (293; 201)
Women
No of deaths
Age-adjusted HR
(95% CI)
Multiple-adjusted{ HR
(95% CI)
Additional deaths{ per 100,000
PY (95% CI)
Sleep length
#5 hours 22 1.22 (0.77; 1.92) 1.21 (0.76; 1.91) 77 (2135; 289)
6 hours 83 1.15 (0.87; 1.52) 1.14 (0.86; 1.52) 47 (251; 146)
7 hours 151 1 (reference) 1 (reference) 0 (Reference)
8 hours 41 0.91 (0.64; 1.30) 0.91 (0.63; 1.30) 226 (2123; 70)
.9 hours 5 1.52 (0.62; 3.73) 1.48 (0.60; 3.65) 148 (2248; 544)
Restless, disturbed nights
Not at all 82 1 (Reference) 1 (Reference) 0 (Reference)
No more than usual 122 1.02 (0.77; 1.35) 1.03 (0.77; 1.36) 8 (284; 101)
More than usual 62 0.96 (0.67; 1.33) 0.97 (0.70; 1.35) 210 (2113; 93)
Joint effect
7–8 h sleep and no sleep disturbances 124 1 (Reference) 1 (Reference) 0 (Reference)
Disturbed sleep only 32 1.02 (0.69; 1.50) 1.03 (0.70; 1.52) 10 (298; 118)
#6 h sleep only 76 1.27 (0.95; 1.69) 1.27 (0.95; 1.69) 88 (222; 198)
#6 h sleep & disturbed sleep 29 1.03 (0.68; 1.54) 1.03 (0.69; 1.55) 6 (2130; 102)
Interaction
P-value for interaction 0.44 0.42 0.35
Additional deaths due to interaction 291 (2285; 102)
{Adjusted for age, employment grade, ethnicity, and marital status.
doi:10.1371/journal.pone.0091965.t002
Sleep and Cause-Specific Mortality
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e91965
T
a
b
le
3
.
(M
e
n
):
C
au
se
-s
p
e
ci
fi
c
m
o
rt
al
it
y
as
so
ci
at
e
d
w
it
h
sl
e
e
p
d
u
ra
ti
o
n
an
d
d
is
tu
rb
e
d
sl
e
e
p
am
o
n
g
6
,1
1
4
m
e
n
fr
e
e
o
f
p
re
-e
xi
st
in
g
d
is
e
as
e
(c
ar
d
io
va
sc
u
la
r
d
is
e
as
e
,
d
ia
b
e
te
s,
ca
n
ce
r,
re
sp
ir
at
o
ry
d
is
o
rd
e
rs
)
fr
o
m
th
e
W
h
it
e
h
al
l
II
st
u
d
y.
C
V
D
m
o
rt
a
li
ty
C
a
n
ce
r
m
o
rt
a
li
ty
O
th
e
r
d
e
a
th
s
N
*
A
g
e
-a
d
ju
st
e
d
H
R
(9
5
%
C
I)
M
u
lt
ip
le
-
a
d
ju
st
e
d
{
H
R
(9
5
%
C
I)
A
d
d
it
io
n
a
l
d
e
a
th
s{
p
e
r
1
0
0
,0
0
0
P
Y
(9
5
%
C
I)
N
*
A
g
e
-a
d
ju
st
e
d
H
R
(9
5
%
C
I)
M
u
lt
ip
le
-
a
d
ju
st
e
d
{
H
R
(9
5
%
C
I)
A
d
d
it
io
n
a
l
d
e
a
th
s{
p
e
r
1
0
0
,0
0
0
P
Y
(9
5
%
C
I)
N
*
A
g
e
-a
d
ju
st
e
d
H
R
(9
5
%
C
I)
M
u
lt
ip
le
-
a
d
ju
st
e
d
{
H
R
(9
5
%
C
I)
A
d
d
it
io
n
a
l
d
e
a
th
s*
p
e
r
1
0
0
,0
0
0
P
Y
(9
5
%
C
I)
S
le
e
p
le
n
g
th
#
6
h
o
u
rs
6
3
1
.3
1
(0
.9
6
;
1
.7
9
)
1
.1
8
(0
.8
7
;
1
.6
3
)
1
9
(2
1
8
;
5
5
)
7
8
1
.1
4
(0
.8
7
;
1
.5
0
)
1
.1
2
(0
.8
5
;
1
.4
8
)
1
7
(2
2
5
;
5
9
)
5
4
1
.3
1
(0
.9
4
;
1
.8
4
)
1
.2
3
(0
.8
8
;
1
.7
4
)
2
0
(2
1
4
;
5
5
)
7
–
8
h
o
u
rs
1
0
2
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
1
4
4
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
8
8
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
.
9
h
o
u
rs
2
2
.1
9
(0
.5
4
;
8
.8
8
)
1
.6
1
(0
.4
0
;
6
.5
9
)
6
2
(2
1
9
5
;
3
1
9
)
2
1
.4
9
(0
.3
7
;
6
.0
2
)
1
.4
7
(0
.3
6
;
5
.9
4
)
5
5
(2
2
0
7
;
3
1
8
)
1
1
.2
3
(0
.1
7
;
8
.8
1
)
1
.0
3
(0
.1
4
;
7
.4
0
)
2
3
(2
1
8
2
;
1
7
7
)
R
e
st
le
ss
,
d
is
tu
rb
e
d
n
ig
h
ts
N
o
t
at
al
l
6
2
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
8
7
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
5
0
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
N
o
m
o
re
th
an
u
su
al
7
3
0
.9
0
(0
.6
4
;
1
.2
6
)
0
.9
3
(0
.6
6
;
1
.3
0
)
2
7
(2
4
2
;
2
9
)
1
0
2
0
.8
9
(0
.6
7
;
1
.1
8
)
0
.8
9
(0
.6
7
;
1
.1
8
)
2
1
8
(2
5
9
;
2
4
)
6
8
1
.0
4
(0
.7
2
;
1
.5
0
)
1
.0
5
(0
.7
3
;
1
.5
2
)
5
(2
2
9
;
3
9
)
M
o
re
th
an
u
su
al
3
2
1
.0
2
(0
.6
6
;
1
.5
6
)
1
.0
8
(0
.7
0
;
1
.6
6
)
8
(2
3
6
;
5
2
)
3
5
0
.7
8
(0
.5
3
;
1
.1
6
)
0
.7
7
(0
.5
2
;
1
.1
5
)
2
3
2
(2
7
9
;
1
6
)
2
5
0
.9
8
(0
.6
0
;
1
.5
8
)
1
.0
0
(0
.6
1
;
1
.6
1
)
1
(2
3
6
;
3
7
)
Jo
in
t
e
ff
e
ct
7
–
8
h
sl
e
e
p
an
d
n
o
sl
e
e
p
d
is
tu
rb
an
ce
s
8
9
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
1
2
1
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
7
8
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
D
is
tu
rb
e
d
sl
e
e
p
o
n
ly
1
3
0
.7
8
(0
.4
4
;
1
.4
0
)
0
.8
2
(0
.4
6
;
1
.4
7
)
2
1
3
(2
5
6
;
2
9
)
2
3
1
.0
1
(0
.6
4
;
1
.5
7
)
1
.0
0
(0
.6
4
;
1
.5
6
)
1
(2
5
4
;
5
6
)
1
0
0
.6
8
(0
.3
5
;
1
.3
1
)
0
.6
8
(0
.3
5
;
1
.3
2
)
2
2
3
(2
5
9
;
1
3
)
#
6
h
sl
e
e
p
o
n
ly
4
4
1
.1
5
(0
.8
0
;
1
.6
5
)
1
.0
4
(0
.7
2
;
1
.4
9
)
3
(2
3
8
;
4
5
)
6
6
1
.2
5
(0
.9
3
;
1
.6
9
)
1
.2
3
(0
.9
3
;
1
.6
9
)
3
3
(2
1
8
;
8
3
)
3
9
1
.1
7
(0
.8
0
;
1
.7
2
)
1
.1
0
(0
.7
5
;
1
.6
2
)
9
(2
3
2
;
5
0
)
#
6
h
sl
e
e
p
&
d
is
tu
rb
e
d
sl
e
e
p
1
9
1
.6
6
(1
.0
1
;
2
.7
3
)
1
.5
7
(0
.9
6
;
2
.5
8
)
5
7
(2
1
6
;
1
3
1
)
1
2
0
.7
6
(0
.4
2
;
1
.3
8
)
0
.7
5
(0
.4
1
;
1
.3
5
)
2
3
2
(2
9
4
;
2
9
)
1
5
1
.4
9
(0
.8
6
;
2
.5
9
)
1
.4
3
(0
.8
2
;
2
.4
8
)
3
9
(2
2
6
;
1
0
4
)
In
te
ra
ct
io
n
P
-v
al
u
e
fo
r
in
te
ra
ct
io
n
0
.1
3
0
.1
3
0
.1
4
0
.2
0
0
.2
0
0
.1
5
0
.1
6
0
.1
6
0
.2
0
A
d
d
it
io
n
al
d
e
at
h
s
d
u
e
to
in
te
ra
ct
io
n
6
7
(2
2
3
;
1
5
7
)
2
6
6
(2
1
5
5
;
2
4
)
5
3
(2
2
8
;
1
3
4
)
*
N
o
.
o
f
ca
u
se
-s
p
e
ci
fi
c
d
e
at
h
s.
{ A
d
ju
st
e
d
fo
r
ag
e
,
e
m
p
lo
ym
e
n
t
g
ra
d
e
,
e
th
n
ic
it
y,
an
d
m
ar
it
al
st
at
u
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
1
9
6
5
.t
0
0
3
Sleep and Cause-Specific Mortality
PLOS ONE | www.plosone.org 6 April 2014 | Volume 9 | Issue 4 | e91965
T
a
b
le
4
.
(W
o
m
e
n
):
C
au
se
-s
p
e
ci
fi
c
m
o
rt
al
it
y
as
so
ci
at
e
d
w
it
h
sl
e
e
p
d
u
ra
ti
o
n
an
d
d
is
tu
rb
e
d
sl
e
e
p
am
o
n
g
2
,9
8
4
w
o
m
e
n
fr
e
e
o
f
p
re
-e
xi
st
in
g
d
is
e
as
e
(c
ar
d
io
va
sc
u
la
r
d
is
e
as
e
,d
ia
b
e
te
s,
ca
n
ce
r,
re
sp
ir
at
o
ry
d
is
o
rd
e
rs
)
fr
o
m
th
e
W
h
it
e
h
al
l
II
st
u
d
y.
C
V
D
m
o
rt
a
li
ty
C
a
n
ce
r
m
o
rt
a
li
ty
O
th
e
r
d
e
a
th
s
N
*
A
g
e
-a
d
ju
st
e
d
H
R
(9
5
%
C
I)
M
u
lt
ip
le
-
a
d
ju
st
e
d
{
H
R
(9
5
%
C
I)
A
d
d
it
io
n
a
l
d
e
a
th
s{
p
e
r
1
0
0
,0
0
0
P
Y
(9
5
%
C
I)
N
*
A
g
e
-a
d
ju
st
e
d
H
R
(9
5
%
C
I)
M
u
lt
ip
le
-
a
d
ju
st
e
d
{
H
R
(9
5
%
C
I)
A
d
d
it
io
n
a
l
d
e
a
th
s{
p
e
r
1
0
0
,0
0
0
P
Y
(9
5
%
C
I)
N
*
A
g
e
-a
d
ju
st
e
d
H
R
(9
5
%
C
I)
M
u
lt
ip
le
-
a
d
ju
st
e
d
{
H
R
(9
5
%
C
I)
A
d
d
it
io
n
a
l
d
e
a
th
s*
p
e
r
1
0
0
,0
0
0
P
Y
(9
5
%
C
I)
S
le
e
p
le
n
g
th
#
6
h
o
u
rs
2
8
1
.8
7
(1
.0
9
;
3
.1
9
)
1
.8
1
(1
.0
5
;
3
.1
0
)
4
6
(2
;
8
9
)
5
6
1
.1
0
(0
.7
9
;
1
.5
3
)
1
.0
9
(0
.7
8
;
1
.5
2
)
1
8
(2
4
8
;
8
3
)
1
8
0
.8
1
(0
.4
6
;
1
.4
2
)
0
.8
4
(0
.4
8
;
1
.4
7
)
2
1
4
(2
5
2
;
2
5
)
7
–
8
h
o
u
rs
2
6
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
9
1
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
3
9
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
.
9
h
o
u
rs
0
n
/a
n
/a
n
/a
3
1
.6
4
(0
.5
2
;
5
.1
9
)
1
.7
0
(0
.5
3
;
5
.3
8
)
1
1
8
(2
2
0
1
;
4
3
7
)
2
1
.1
8
(0
.1
6
;
8
.6
3
)
1
.1
5
(0
.1
6
;
8
.4
0
)
1
4
(2
1
7
0
;
1
9
7
)
R
e
st
le
ss
,
d
is
tu
rb
e
d
n
ig
h
ts
N
o
t
at
al
l
1
0
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
5
2
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
1
7
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
N
o
m
o
re
th
an
u
su
al
2
3
1
.5
6
(0
.7
4
;
3
.2
8
)
1
.6
9
(0
.8
0
;
3
.5
6
)
2
5
(2
1
1
;
6
0
)
6
7
0
.8
9
(0
.6
2
;
1
.2
8
)
0
.8
8
(0
.6
1
;
1
.2
6
)
2
2
5
(2
9
5
;
4
5
)
3
1
1
.2
4
(0
.6
8
;
2
.2
4
)
1
.2
3
(0
.6
8
;
2
.2
3
)
1
7
(2
2
8
;
6
1
)
M
o
re
th
an
u
su
al
2
1
2
.6
6
(1
.2
5
;
5
.6
5
)
3
.0
4
(1
.4
2
;
6
.5
1
)
7
0
(1
9
;
1
2
1
)
3
1
0
.7
6
(0
.4
9
;
1
.1
8
)
0
.7
4
(0
.4
7
;
1
.1
6
)
2
5
3
(2
1
2
9
;
2
4
)
1
0
0
.7
4
(0
.3
4
;
1
.6
1
)
0
.7
3
(0
.3
3
;
1
.6
1
)
2
1
7
(2
6
1
;
2
7
)
Jo
in
t
e
ff
e
ct
7
–
8
h
sl
e
e
p
an
d
n
o
sl
e
e
p
d
is
tu
rb
an
ce
s
1
7
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
7
4
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
3
3
1
(R
e
fe
re
n
ce
)
1
(R
e
fe
re
n
ce
)
0
(R
e
fe
re
n
ce
)
D
is
tu
rb
e
d
sl
e
e
p
o
n
ly
9
2
.0
9
(0
.9
3
;
4
.7
0
)
2
.3
6
(1
.0
5
;
5
.3
3
)
4
8
(2
7
;
1
0
3
)
1
7
0
.9
1
(0
.5
3
;
1
.5
3
)
0
.9
0
(0
.5
3
;
1
.5
3
)
2
1
7
(2
9
6
;
6
3
)
6
0
.7
1
(0
.3
0
;
1
.7
0
)
0
.7
0
(0
.2
9
;
1
.6
8
)
2
2
2
(2
7
0
;
2
7
)
#
6
h
sl
e
e
p
o
n
ly
1
6
1
.9
1
(0
.9
6
;
3
.7
8
)
1
.8
5
(0
.9
3
;
3
.6
8
)
3
7
(2
1
0
;
8
5
)
4
3
1
.2
1
(0
.8
3
;
1
.7
7
)
1
.2
1
(0
.8
3
;
1
.7
6
)
4
3
(2
4
1
;
1
2
7
)
1
4
0
.8
7
(0
.4
5
;
1
.6
3
)
0
.9
1
(0
.4
8
;
1
.7
0
)
2
8
(2
5
7
;
4
1
)
#
6
h
sl
e
e
p
&
d
is
tu
rb
e
d
sl
e
e
p
1
2
3
.0
9
(1
.4
8
;
6
.4
8
)
3
.1
9
(1
.5
2
;
6
.7
2
)
9
3
(1
0
;
1
7
6
)
1
3
0
.7
7
(0
.4
3
;
1
.3
9
)
0
.7
6
(0
.4
2
;
1
.3
7
)
2
4
9
(2
1
4
2
;
4
5
)
4
0
.5
3
(0
.1
9
;
1
.5
0
)
0
.5
5
(0
.1
9
;
1
.5
5
)
2
3
8
(2
9
2
;
1
6
)
In
te
ra
ct
io
n
P
-v
al
u
e
fo
r
in
te
ra
ct
io
n
0
.6
5
0
.5
8
0
.8
8
0
.4
0
0
.3
9
0
.3
0
0
.8
3
0
.8
4
0
.8
4
A
d
d
it
io
n
al
d
e
at
h
s
d
u
e
to
in
te
ra
ct
io
n
8
(2
9
7
;
1
1
3
)
2
7
5
(2
2
1
9
;
6
8
)
2
8
(2
8
8
;
7
2
)
*
N
o
.
o
f
ca
u
se
-s
p
e
ci
fi
c
d
e
at
h
s.
{ A
d
ju
st
e
d
fo
r
ag
e
,
e
m
p
lo
ym
e
n
t
g
ra
d
e
,
e
th
n
ic
it
y,
an
d
m
ar
it
al
st
at
u
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
1
9
6
5
.t
0
0
4
Sleep and Cause-Specific Mortality
PLOS ONE | www.plosone.org 7 April 2014 | Volume 9 | Issue 4 | e91965
T
a
b
le
5
.
(S
e
n
si
ti
vi
ty
an
al
ys
e
s)
:C
ar
d
io
va
sc
u
la
r
d
is
e
as
e
(C
V
D
)
m
o
rt
al
it
y
as
so
ci
at
e
d
w
it
h
th
e
jo
in
t
e
ff
e
ct
s
o
f
sl
e
e
p
d
u
ra
ti
o
n
an
d
d
is
tu
rb
e
d
sl
e
e
p
am
o
n
g
9
,0
9
8
m
e
n
an
d
w
o
m
e
n
fr
e
e
o
f
p
re
-e
xi
st
in
g
d
is
e
as
e
(c
ar
d
io
va
sc
u
la
r
d
is
e
as
e
,
d
ia
b
e
te
s,
ca
n
ce
r,
re
sp
ir
at
o
ry
d
is
o
rd
e
rs
)
fr
o
m
th
e
W
h
it
e
h
al
l
II
st
u
d
y
in
se
n
si
ti
vi
ty
an
al
ys
e
s.
M
e
n
W
o
m
e
n
7
–
8
h
sl
e
e
p
a
n
d
n
o
sl
e
e
p
d
is
tu
rb
a
n
ce
s
D
is
tu
rb
e
d
sl
e
e
p
o
n
ly
#
6
h
sl
e
e
p
o
n
ly
#
6
h
sl
e
e
p
&
d
is
tu
rb
e
d
sl
e
e
p
7
–
8
h
sl
e
e
p
a
n
d
n
o
sl
e
e
p
d
is
tu
rb
a
n
ce
s
D
is
tu
rb
e
d
sl
e
e
p
o
n
ly
#
6
h
sl
e
e
p
o
n
ly
#
6
h
sl
e
e
p
&
d
is
tu
rb
e
d
sl
e
e
p
4
-y
e
a
r
la
g
N
o
.
o
f
d
e
at
h
s
8
5
1
3
3
9
1
8
1
5
9
1
6
1
2
H
R
{
(9
5
%
C
I)
1
(r
e
fe
re
n
ce
)
0
.8
5
(0
.4
8
;1
.5
3
)
0
.9
7
(0
.6
6
;
1
.4
2
)1
.5
6
(0
.9
4
;
2
.6
0
)
1
(r
e
fe
re
n
ce
)
2
.6
9
(1
.1
7
;
6
.1
8
)
2
.1
1
(1
.0
4
;
4
.2
8
)3
.6
3
(1
.6
9
;
7
.7
9
)
E
x
cl
u
si
o
n
o
f
in
d
iv
id
u
a
ls
w
it
h
B
M
I$
2
5
k
g
/
m
2
N
o
.
o
f
d
e
at
h
s
4
4
9
2
0
4
5
3
7
5
H
R
{
(9
5
%
C
I)
1
(r
e
fe
re
n
ce
)
1
.1
8
(0
.5
8
;
2
.4
3
)
1
.0
7
(0
.6
3
;
1
.8
1
)0
.7
4
(0
.2
6
;
2
.0
5
)
1
(r
e
fe
re
n
ce
)
2
.3
7
(0
.5
6
;
9
.9
5
)
2
.8
6
(0
.9
0
;
9
.0
8
)4
.0
1
(1
.1
5
;
1
4
.0
)
A
d
ju
st
m
e
n
t
fo
r
d
e
p
re
ss
io
n
/a
n
x
ie
ty
*
N
o
.
o
f
d
e
at
h
s
5
9
7
3
5
1
7
1
4
7
1
4
8
H
R
{
(9
5
%
C
I)
1
(r
e
fe
re
n
ce
)
0
.6
8
(0
.3
1
;
1
.5
0
)
1
.1
6
(0
.7
6
;
1
.7
7
)1
.8
7
(1
.0
8
;
3
.2
5
)
1
(r
e
fe
re
n
ce
)
2
.1
5
(0
.8
6
;
5
.3
7
)
2
.0
6
(0
.9
8
;
4
.3
5
)2
.5
3
(1
.0
4
;
6
.1
2
)
A
d
ju
st
m
e
n
t
fo
r
h
e
a
lt
h
b
e
h
a
v
io
u
r
(s
m
o
k
in
g
,
a
lc
o
h
o
l,
p
h
y
si
ca
l
a
ct
iv
it
y
)
N
o
.
o
f
d
e
at
h
s
8
5
1
2
4
2
1
7
1
6
9
1
6
1
1
H
R
{
(9
5
%
C
I)
1
(r
e
fe
re
n
ce
)
0
.8
3
(0
.4
6
;
1
.4
9
)
1
.0
4
(0
.7
1
;
1
.5
1
)1
.6
5
(1
.0
0
;
2
.7
3
)
1
(r
e
fe
re
n
ce
)
2
.4
7
(1
.0
9
;
5
.5
8
)
1
.6
9
(0
.8
3
;
3
.4
0
)2
.9
6
(1
.3
8
;
6
.3
8
)
A
d
ju
st
m
e
n
t
fo
r
C
V
D
ri
sk
fa
ct
o
rs
(s
y
st
o
li
c
b
lo
o
d
p
re
ss
u
re
,
ch
o
le
st
e
ro
l,
B
M
I)
N
o
.
o
f
d
e
at
h
s
8
8
1
3
4
3
1
8
1
5
9
1
6
1
2
H
R
{
(9
5
%
C
I)
1
(r
e
fe
re
n
ce
)
0
.8
7
(0
.4
8
;
1
.5
6
)
1
.0
1
(0
.7
0
;
1
.4
6
)1
.4
6
(0
.8
8
;
2
.4
3
)
1
(r
e
fe
re
n
ce
)
2
.6
6
(1
.1
4
;
6
.1
8
)
2
.0
5
(1
.0
1
;
4
.1
6
)3
.8
1
(1
.7
7
;
8
.2
0
)
*
In
su
b
-s
am
p
le
w
it
h
in
fo
rm
at
io
n
o
n
th
is
va
ri
ab
le
(n
=
6
7
5
6
).
{ A
d
ju
st
e
d
fo
r
ag
e
,
e
m
p
lo
ym
e
n
t
g
ra
d
e
,
e
th
n
ic
it
y,
an
d
m
ar
it
al
st
at
u
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
1
9
6
5
.t
0
0
5
Sleep and Cause-Specific Mortality
PLOS ONE | www.plosone.org 8 April 2014 | Volume 9 | Issue 4 | e91965
sleep disturbances, had a three times higher risk of CVD mortality,
equivalent to approximately one additional death per 1000 person
years. This effect equals that expected from the combination of the
two independent risk factors. We found no noteworthy associa-
tions between any of the sleep measures and deaths due to cancer
or other causes in men or women. Interaction analyses require
large sample sizes and some of the risk estimates from the
interaction analyses were based on relatively few deaths and
should therefore be interpreted with caution. For this reason, we
were also not able to address the interaction between long sleep
duration and disturbed sleep, as we had very few people in this risk
category.
Recent systematic reviews of the literature show that sleep
duration is associated with mortality in a U-shaped fashion, with
the lowest risk found in those who report durations of around
7 hours [2,3]. In the Whitehall II study, both short and long sleep
as well as changes in sleep duration toward either the short or long
end of the sleep duration spectrum have previously been shown to
be associated with higher mortality [17]. Our findings of a higher
risk of all-cause mortality in those who report short or long sleep
are in agreement with these previous findings.
Studies that have examined the associations between sleep and
cause-specific mortality have provided mixed findings [3,4]. Our
findings add to the existing literature by demonstrating sex
differences in the effect of sleep parameters on the risk of CVD
mortality, in addition to addressing the combined effect of short
sleep duration and disturbed sleep on cause-specific mortality for
the first time. Short sleep has previously been shown to be
associated with CVD-related mortality in the Whitehall II study
[17], but the present findings emphasize the importance of also
considering sleep disturbances, either in combination with sleep
duration or as an independent risk factor for CVD mortality.
These findings are in agreement with the findings of two previous
studies, showing a higher risk of CHD incidence among those
exposed to both short sleep duration and disturbed sleep [7,8].
In light of previous studies, the observed sex differences in the
results for CVD mortality are not surprising. We find both short
sleep duration and sleep disturbances to be stronger risk factors for
CVD mortality in women than in men and to account for a higher
proportion of CVD deaths. Some of these differences may be
explained by recently observed sex differences in the associations
between sleep and cardiovascular risk factors and inflammatory
markers [6,18,19]. In a French cohort study with annual data,
sleep disturbances were associated with a higher risk of developing
both hypertension and diabetes with the strongest effects observed
for women [6]. Sex differences in the relation between sleep
duration and hypertension have also been found previously in the
Whitehall II study, with short sleep being associated with
prevalence and incidence of hypertension in women only [18].
Low grade inflammation is assumed to be a factor in the
development of cardiovascular disease [20], and an association
between sleep duration and inflammatory markers has previously
been shown for women, but not men, in the present study
population [19]. The hypothalamic-pituitary-adrenal axis has also
been proposed as a potential mechanism by which impaired sleep
might be associated with poor health [21], and it has been shown
that short sleep and sleep disturbances are independently
associated with an increased cortisol awakening response and a
flatter diurnal slope in cortisol secretion in the Whitehall II study,
although no sex differences were observed in these associations
[22].
Limitations
Inadequate or disturbed sleep may simply be markers of existing
morbidity, and it is well known that people who report shorter or
longer sleep often are more likely to be in poorer overall health
and have been diagnosed with medical conditions, including
depression [3]. Although we cannot fully rule out this explanation,
we tried to accommodate such concerns by restricting all analyses
to individuals without pre-existing disease. In sensitivity analyses,
we also excluded deaths within the first four years of follow-up
from the statistical analyses, but found very similar results to those
in the main analysis. Adjustment for self-reported nervous trouble
and persistent depression in a sensitivity analyses slightly
attenuated the higher risk of CVD mortality associated with short
and disturbed sleep observed in women, but not in men. Although
attenuated after adjustment for depression, women with short and
disturbed sleep still showed more than twice the risk of CVD
mortality compared to women with 7–8 hours of sleep and no
sleep disturbances.
Like most large population-based studies, we lacked information
on sleep apnea, a major and prevalent sleep disorder. Sleep apnea
often results in disturbed sleep and also constitutes a risk factor for
premature death and CVD [23,24], making confounding by sleep
apnea a concern. Since sleep apnea is less common in people of
normal weight, we repeated our analyses in a subset of the
population with BMI,25 kg/m2. In this subset of the population
a higher CVD mortality risk was not found among men who
experienced both short and disturbed sleep, while women with
both risk factors still appeared to confer a markedly higher risk of
CVD mortality. The number of CVD cases was severely reduced
in this analysis, which makes it difficult to separate confounding
from statistical variability. Sleep apnea often goes undiagnosed for
many years and it has been estimated that as many as 75% of
severe cases of sleep disordered breathing remain undiagnosed
[25]. Disturbed sleep may therefore in some cases be understood
as a marker of underlying sleep disorders instead of an
independent risk factor.
Our information on sleep relied on two single-item self-reported
questions on sleep duration and disturbed sleep, which is likely to
have resulted in some misclassification. Unfortunately, it is often
not feasible to obtain objective measures of sleep in large
population samples, and self-reported assessments of sleep have
previously been shown to be a reasonably valid estimate of
quantitative sleep assessed by diary, actigraph, or polysomnogra-
phy data [26–28]. In addition, assessments of sleep durations in
the primary health care setting rely on self-reported data from
patients making such simple questions relevant in terms of risk
prediction. More detailed questionnaire-based information on
sleep patterns including naps, sleep efficiency and validated scales
for assessment of sleep disturbances would have been preferable
and the lack of more detailed sleep measures may have resulted in
some degree of misclassification. Finally, we were not able take
changes in sleep patterns over time into account and such potential
misclassification may have resulted in an underestimation of the
risk estimates.
This study has also several strengths. It is the first large-scale
study to describe the combined effect of short sleep duration and
disturbed sleep on cause-specific mortality. Longitudinal data from
a well-characterized cohort enabled us to adjust for a number of
well-known confounders of the sleep-mortality association, and
detailed information on pre-existing disease at baseline allowed us
to restrict the study population to those without such diseases.
Linkage to a nationwide death registry enabled identification of
virtually all deaths and allowed for nearly complete long-term
follow-up. Application of a newly proposed method to address
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additive interaction in survival analyses allowed us to directly
estimate potential deviation from additivity of effects as well as
assess the absolute effects of each sleep parameter independently
and jointly, providing a clinically relevant estimate of additional
deaths associated with the sleep variables.
Conclusion
Poor sleep is a common and increasing public health problem in
westernized countries. We find both short sleep duration and
disturbed sleep to be strong independent indicators of CVD
mortality in women. In men, evidence for a higher risk of CVD
mortality in relation to these sleep parameters did not reach
statistical significance, but suggests a slightly elevated risk among
those exposed to both short sleep duration and disturbed sleep.
Disturbed sleep may be an indicator of underlying sleep apnea,
and future population-based studies may benefit from assessing
disturbed sleep in addition to sleep duration in order to capture
health-relevant features of inadequate sleep.
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